Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01341301 · ClinicalTrials.gov registry record · Phase 2
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT01341301 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 25 participants.
The verdict
NCT01341301, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this research study is to examine the survival of patients undergoing partially matched hematopoietic stem cell transplant (HSCT) on a new type of treatment approach, which has been developed specifically for patients who have evidence of their disease at the time of transplant. In this research study, a way of strengthening the response of the donor cells against the disease has been developed. Patients will undergo one additional day between the two steps of the transplant which may allow their donor's cells to fight the disease more effectively.
Interventions
- DRUG Cyclophosphamide
- DRUG Tacrolimus
- RADIATION Total Body Irradiation
- DRUG Mycophenolate mofetil
- BIOLOGICAL Donor Lymphocyte Infusion (DLI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2010-05 |
| Est. Completion | 2014-08-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01341301
The ClinicalTrials.gov registry entry for NCT01341301 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT01341301 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01341301 about?
NCT01341301 is a clinical study titled "Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies". The purpose of this research study is to examine the survival of patients undergoing partially matched hematopoietic stem cell transplant (HSCT) on a new type of treatment approach, which has been developed specifically for patients who have evidence of their disease at the time of transplant. In th...
What is the current status of trial NCT01341301?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2010-05. Estimated completion is 2014-08-07.
What interventions are being tested in trial NCT01341301?
The interventions under investigation include: Cyclophosphamide (DRUG), Tacrolimus (DRUG), Total Body Irradiation (RADIATION), Mycophenolate mofetil (DRUG), Donor Lymphocyte Infusion (DLI) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01341301?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.